ストックスクリーナーアプリを入手
21.32
0.61%
0.13
アフターアワーズ：
21.32
前日終値:
$21.19
開ける：
$21.17
24時間の取引高:
685.05K
Relative Volume:
0.48
時価総額：
$1.37B
収益：
$2.62B
当期純損益:
$966.70M
株価収益率:
14.21
EPS:
1.5004
ネットキャッシュフロー:
$1.09B
1週間 パフォーマンス:
+1.38%
1か月 パフォーマンス:
+2.55%
6か月 パフォーマンス:
-0.84%
1年 パフォーマンス:
-23.83%
1日の値動き範囲:
$21.11
$21.41
1週間の範囲:
$20.52
$21.41
52週間の値動き範囲:
$17.23
$28.96
Genmab Adr Stock (GMAB) Company Profile
GMAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
21.32 | 12.95B | 2.62B | 966.70M | 1.09B | 1.5004 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-01 | ダウングレード | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | 開始されました | Redburn Atlantic | Buy |
| 2024-09-04 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-08-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | ダウングレード | Citigroup | Neutral → Sell |
| 2023-12-06 | アップグレード | UBS | Neutral → Buy |
| 2023-11-10 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-11-08 | アップグレード | DNB Markets | Sell → Buy |
| 2023-10-18 | 開始されました | Exane BNP Paribas | Underperform |
| 2023-09-06 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | 開始されました | BTIG Research | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-31 | 開始されました | UBS | Neutral |
| 2023-05-12 | 開始されました | Morgan Stanley | Underweight |
| 2022-12-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-11-14 | 開始されました | William Blair | Mkt Perform |
| 2022-11-11 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2022-06-24 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-05-02 | 開始されました | Cowen | Market Perform |
| 2022-03-16 | アップグレード | UBS | Neutral → Buy |
| 2022-01-31 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-12-01 | 開始されました | Berenberg | Sell |
| 2021-09-16 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | 開始されました | Deutsche Bank | Buy |
| 2021-01-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | ダウングレード | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-06-25 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | 開始されました | Credit Suisse | Outperform |
| 2020-02-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-12-12 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2019-09-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-08-12 | 開始されました | Guggenheim | Buy |
| 2019-08-12 | 開始されました | Morgan Stanley | Overweight |
| 2019-08-12 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Genmab Adr (GMAB) 最新ニュース
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Applied Dna Sciences Inc (APDN)’s Day in Review: Closing at 0.85, Down by -2.41 - DWinneX
Stock Surge: Genmab ADR (GMAB) Closes at 19.42, Marking a -5.73 Increase/Decrease - DWinneX
Market Momentum Report: Evercore Inc (EVR)’s Positive Close at 216.74 - DWinneX
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) - GlobeNewswire Inc.
Investing in Take-Two Interactive Software, Inc (TTWO) Is Getting More Attractive - knoxdaily.com
Investing in Genmab ADR (GMAB): What You Must Know - knoxdaily.com
Nucor Corp (NUE) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
EWTX Stock Sees Surge of Approximately 4.24% in Last Five Days - knoxdaily.com
GMAB or RGEN: Which Is the Better Value Stock Right Now? - Yahoo Finance
Should Value Investors Buy Genmab (GMAB) Stock? - Yahoo Finance
Genmab ADR (NASDAQ: GMAB) Jumps 1.19% In Recent Session. Here’s Everything You Need To Know. - Stocksregister
AGCO Corp (AGCO) Beta Value: Understanding the Market Risk - News Heater
Evercore Inc’s Mixed Bag: Down -29.24% in 6 Months, Down -20.22% in 30 Days - investchronicle.com
GMAB’s Debt-to-Equity Ratio at 0.03: What It Means for Genmab ADR’s Future - investchronicle.com
CZR Stock Sees Decline of Approximately -4.82% in Last Five Days - knoxdaily.com
Magnite Inc (MGNI) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
DLocal Limited (DLO) Shares Decline Despite Market Challenges - The News Heater
Genmab ADR Inc. (GMAB) Price Performance: The Role of Supply and Demand - The InvestChronicle
Views of Wall Street’s Leading Experts on Genmab ADR - SETE News
What is Core & Main Inc (CNM) Stock Return on Shareholders’ Capital? - SETE News
There is no doubt that Kite Realty Group Trust (KRG) ticks all the boxes. - SETE News
Sea Ltd ADR (NYSE: SE) Jumps 4.64%, Turning Investors Away - Stocks Register
Does Genmab ADR (NASDAQ: GMAB) Still Look Hot This Week? - Stocks Register
Genmab (GMAB) Upgraded to Buy: Here's What You Should Know - MSN
GMAB vs. QGEN: Which Stock Is the Better Value Option? - MSN
Are Investors Undervaluing Genmab (GMAB) Right Now? - Yahoo Finance
Genmab stock holds Buy rating on positive trial results - Investing.com
10 Biggest Biotechnology Companies - Investopedia
Weekly Upgrades and Downgrades - InvestorPlace
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock? - Yahoo Finance
Is Genmab (GMAB) Stock Undervalued Right Now? - Yahoo Finance
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround - Yahoo Finance
RBC Capital upgrades Genmab stock amid strong pipeline prospects - Investing.com
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma - Yahoo Finance
Genmab's 'Evolution' Continues With A $1.8 Billion Deal; But Shares Slip - Investor's Business Daily
GMAB: Bank on the Future Returns With These 3 Biotech Stocks - StockNews
Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results - MarketWatch
Genmab ADR Getting Closer To Key Technical Measure - Investor's Business Daily
Stocks Flashing Renewed Technical Strength: Ascendis Pharma ADR - Investor's Business Daily
GILD or GMAB: Which Is the Better Value Stock Right Now? - Yahoo News Canada
New Strong Buy Stocks for January 11th - Yahoo Finance
Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates - Yahoo
INCY vs. GMAB: Which Stock Is the Better Value Option? - Yahoo Finance
Genmab Adr (GMAB) 財務データ
収益
当期純利益
現金流量
EPS
0.95%
大文字化:
|
ボリューム (24 時間):